Who makes Early measles vaccine?

Early measles vaccine is developed by Bandim Health Project.

What development phase is Early measles vaccine in?

Early measles vaccine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Early measles vaccine

Bandim Health Project · FDA-approved active Biologic Quality 5/100

At a glance

Generic name	Early measles vaccine
Sponsor	Bandim Health Project
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. (PHASE4)
Trial of Additional Measles Vaccine to Reduce Child Mortality (PHASE4)
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (PHASE1, PHASE2)
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age (PHASE4)
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings (PHASE2)
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (PHASE1)
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Early measles vaccine CI brief — competitive landscape report
Early measles vaccine updates RSS · CI watch RSS
Bandim Health Project portfolio CI